|
|
| (One intermediate revision by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Fluvastatin]] |
| {{fluvastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to [[hypercholesterolemia]]. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate.
| |
| | |
| ===[[hypercholesterolemia]] (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia===
| |
| | |
| LESCOL and LESCOL XL are indicated
| |
| | |
| *as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and apolipoprotein B (Apo B) levels, and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary [[hypercholesterolemia]] and mixed dyslipidemia (Fredrickson Type IIa and IIb).
| |
| *as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and adolescent girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial [[hypercholesterolemia]] and the following findings are present:
| |
| **LDL-C remains ≥ 190 mg/dL or
| |
| **LDL-C remains ≥ 160 mg/dL and:
| |
| ***there is a positive family history of premature cardiovascular disease or
| |
| ***two or more other cardiovascular disease risk factors are present
| |
| | |
| The NCEP classification of cholesterol levels in pediatric patients with a familial history of [[hypercholesterolemia]] or premature CVD is summarized below.
| |
| | |
| {|
| |
| |[[File:fluvastatin01.jpg|thumb|800px]]
| |
| |}
| |
| | |
| Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals.
| |
| | |
| | |
| ===Secondary Prevention of Cardiovascular Disease===
| |
| | |
| In patients with clinically evident CHD, LESCOL and LESCOL XL are indicated to:
| |
| | |
| reduce the risk of undergoing coronary revascularization procedures
| |
| slow the progression of coronary atherosclerosis
| |
| | |
| ===Limitations of Use===
| |
| | |
| Neither LESCOL nor LESCOL XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LESCOL (FLUVASTATIN SODIUM) CAPSULE LESCOL XL (FLUVASTATIN SODIUM) TABLET, EXTENDED RELEASE [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a1823e7-26fb-4858-bac7-9e152e5ea16a | publisher = | date = | accessdate = 12 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Statins]]
| |
| [[Category:Diols]]
| |
| [[Category:Indoles]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Organofluorides]]
| |
| [[Cardiovasular Druf]]
| |
| [[Drug]]
| |